Want to see GB:STX full AI Analyst Report?
Top Page
Shield Therapeutics
(LSE:STX)
Select Model
Select Model
Rating:46Neutral
Price Target:
6.00 p
▲(23.71% Upside)
Action:Reiterated
Date:09/26/26
The score is held down primarily by weak financial strength—ongoing losses, continued cash burn, and negative equity—despite clear improvement in revenue growth and margins. Technicals are mixed with neutral momentum and a still-weak longer-term trend, while valuation is constrained by the negative P/E and no dividend yield data.
Positive Factors
Strong revenue growth
Revenue growth of 58.2% demonstrates strong commercial progress for the company’s lead product and expands the base from which future profitability can develop. Continued top-line expansion over the next several quarters could improve operating leverage and support greater investment in commercialization.
Negative Factors
Continued net losses
Despite rapid revenue growth and improved margins, the company remains substantially loss-making, showing that current commercial scale is not yet sufficient to cover the full cost base. Persistent losses could delay self-sustaining profitability and require further operational improvement before earnings become durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Revenue growth of 58.2% demonstrates strong commercial progress for the company’s lead product and expands the base from which future profitability can develop. Continued top-line expansion over the next several quarters could improve operating leverage and support greater investment in commercialization.
Read all positive factors
Shield Therapeutics (STX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£59.08M
Dividend YieldN/A
Average Volume (3M)1.73M
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue Growth36.19%
EPS Growth60.75%
CountryUK
Employees61
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,074,157,600
10 Day Avg. Volume1,060,628
30 Day Avg. Volume1,725,392
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-5.76
Price to Sales (P/S)1.71
P/FCF Ratio-9.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£72.63M
Shield Therapeutics Business Overview & Revenue Model
Company Description
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral...
How the Company Makes Money
Shield Therapeutics makes money primarily from the commercialization of its lead product, Accrufer®/Feraccru® (ferric maltol). The main revenue streams are: (1) Product sales: revenue generated from selling Accrufer/Feraccru in markets where the c...
Shield Therapeutics Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
27
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.51M | 50.74M | 32.18M | 16.54M | 4.48M | 1.52M |
| Gross Profit | 29.59M | 22.38M | 13.22M | 5.09M | 2.00M | -1.67M |
| EBITDA | -3.22M | -9.16M | -21.26M | -38.28M | -46.61M | -17.69M |
| Net Income | -2.23M | -18.03M | -26.61M | -33.29M | -40.44M | -19.34M |
Balance Sheet | ||||||
| Total Assets | 53.92M | 65.24M | 57.42M | 48.80M | 22.07M | 44.41M |
| Cash, Cash Equivalents and Short-Term Investments | 8.39M | 11.63M | 7.02M | 17.63M | 2.82M | 12.12M |
| Total Debt | 25.03M | 30.15M | 26.34M | 25.80M | 6.10M | 156.00K |
| Total Liabilities | 71.04M | 80.32M | 58.74M | 33.77M | 16.65M | 3.38M |
| Stockholders Equity | -17.11M | -15.08M | -1.32M | 11.79M | 5.43M | 40.69M |
Cash Flow | ||||||
| Free Cash Flow | -12.31M | -8.83M | -8.80M | -50.65M | -20.14M | -18.80M |
| Operating Cash Flow | -12.26M | -8.81M | -8.77M | -46.93M | -18.25M | -16.74M |
| Investing Cash Flow | 949.89K | -306.29K | -2.37M | -3.07M | -1.70M | -2.05M |
| Financing Cash Flow | 9.09M | 13.75M | 5.26M | 62.77M | 7.71M | 27.58M |
Shield Therapeutics Technical Analysis
Neutral
4.85
Price Trends
5.19
Positive
5.45
Positive
7.15
Negative
Market Momentum
0.08
Negative
54.05
Neutral
75.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:STX, the sentiment is Neutral. The current price of 4.85 is below the 20-day moving average (MA) of 5.53, below the 50-day MA of 5.19, and below the 200-day MA of 7.15, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 54.05 is Neutral, neither overbought nor oversold. The STOCH value of 75.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:STX.
Shield Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | £79.55M | 15.37 | 7.82% | 0.10% | ― | ― | |
70 Outperform | £3.52B | 12.67 | 15.05% | 3.73% | 2.48% | 3.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | £59.08M | -7.49 | 64.57% | ― | 36.19% | 60.75% | |
42 Neutral | £269.13M | -4.29 | 409.00% | ― | 2.94% | -32.00% |
* Healthcare Sector Average
GB:STX
Shield Therapeutics
5.50
-1.45
-20.86%
GB:AGY
Allergy Therapeutics
4.25
-3.95
-48.17%
GB:HIK
Hikma Pharmaceuticals
1,700.00
11.75
0.70%
GB:VLG
Venture Life
67.00
12.00
21.82%
Shield Therapeutics Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Shield Therapeutics updates total voting rights and share capital
Positive
Sep 30, 2026
Shield Therapeutics has confirmed that its issued share capital now comprises 1,074,157,593 ordinary shares of 1.5 pence each, all carrying equal voting rights and with no shares held in treasury. This update provides investors with the official s...
Business Operations and StrategyRegulatory Filings and Compliance
Shield Therapeutics Updates Total Voting Rights as Iron Drug Growth Continues
Positive
Sep 1, 2026
Shield Therapeutics has confirmed that its issued share capital stands at 1,069,911,197 ordinary shares, each carrying equal voting rights, with no shares held in treasury. This total voting rights figure provides the reference denominator for sha...
Business Operations and StrategyFinancial Disclosures
Shield Therapeutics Takes Full Control of U.S. ACCRUFeR Business to Boost Profitability
Positive
Aug 27, 2026
Shield Therapeutics has struck an agreement with Viatris under which it will assume full commercial responsibility for ACCRUFeR® in the United States, its largest and fastest-growing market, from the end of September 2026. The deal transfers ...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Shield Therapeutics narrows losses as ACCRUFeR® growth and global milestones lift H1 revenue
Positive
Aug 20, 2026
Shield Therapeutics reported unaudited interim results showing group revenues of $30.4 million for the first half of 2026, up 42% year-on-year, driven by U.S. sales of ACCRUFeR® and a sharp rise in ex-U.S. milestones and royalties. The group ...
Business Operations and StrategyRegulatory Filings and Compliance
Shield Therapeutics updates total voting rights and underscores global iron therapy push
Positive
Aug 3, 2026
Shield Therapeutics has confirmed that its issued share capital comprises 1,069,911,197 ordinary shares of 1.5p each, all carrying equal voting rights and with no shares held in treasury. This disclosure updates investors on the total voting right...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Shield Therapeutics grows H1 revenue, pivots commercial strategy and appoints new CFO
Positive
Jul 30, 2026
Shield Therapeutics reported unaudited H1 2026 revenues of $30.4M, up from $21.5M a year earlier, helped by a $7.9M milestone payment from its Chinese partner ASK and higher royalties, keeping the group profitable in the half. Q2 net revenue was $...
Business Operations and StrategyProduct-Related Announcements
Shield’s pediatric trial backs ferric maltol in childhood iron deficiency anemia
Positive
Jul 28, 2026
Shield Therapeutics has reported that results from its Phase 3 FORTIS pediatric trial of ferric maltol have been published in the journal Pediatric Drugs, reinforcing the drug’s role in managing iron deficiency anemia in children. The study ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.